Trials / Unknown
UnknownNCT00591383
Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Alaunos Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Single arm, open label, Phase I, dose-escalation study of indibulin in combination with erlotinib in subjects with advanced histologically confirmed, solid tumors for which no standard therapy exists and for whom treatment with erlotinib is considered medically acceptable.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | indibulin | indibulin, dose escalation, 200 mg - 600 mg. Taken twice every day. |
| DRUG | erlotinib | erlotinib taken at 150 mg every morning with food. |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2013-06-01
- Completion
- 2013-06-01
- First posted
- 2008-01-11
- Last updated
- 2012-07-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00591383. Inclusion in this directory is not an endorsement.